Additional Study Information: The purpose of the study is to test the safety of an investigational/study drug called BMS-986207 (also known as Anti TIGIT monoclonal antibody) administered alone and in combination with nivolumab. This study will investigate how research subjects/participants with advanced solid tumors tolerate these drugs and identify the highest dose or most suitable dose, of BMS-986207 alone and in combination with nivolumab, in cancer research subjects/participants. This is the first study in which BMS-986207 will be administered to humans. Nivolumab has been administered to and is approved for human use in multiple tumor types. Cancers include Colon cancer, rectal cancer, ovarian cancer, liver cancer, and lung cancer.